QuidelOrtho's Secondary Offering Signals Major Change in Shareholder Structure and Governance

QuidelOrtho's Secondary Offering Marks Significant Shift in Shareholder Dynamics

QuidelOrtho Corporation, a prominent player in the in vitro diagnostics sector, announces a secondary offering of 8,260,183 shares of its common stock, driven by Carlyle Partners VI Cayman Holdings, L.P. as the Selling Stockholder. Importantly, QuidelOrtho will not participate in this offering by selling any of its shares or receiving any proceeds, marking a distinct shift in its ownership landscape. This move is significant as it allows Carlyle Partners to exit its investment in QuidelOrtho, a step that will culminate with the termination of their Principal Stockholders Agreement. Following the offering, Carlyle will lose its rights to nominate members to QuidelOrtho's Board of Directors, signaling a transition in the governance of the company.

As the offering is set to close on November 21, 2024, under the guidance of Goldman Sachs & Co. LLC, the shares will be made available to the public at a fixed price, although this price may fluctuate without prior notice. The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Interested investors are encouraged to consult the prospectus and related documentation to fully understand the terms of the offering. This strategic move allows QuidelOrtho to maintain its focus on innovation in diagnostics, as the transaction is solely for the benefit of the Selling Stockholder.

QuidelOrtho's management underscores that this announcement is not an offer to sell or a solicitation to buy these securities, particularly in jurisdictions where such activities would violate local laws. Furthermore, the press release includes cautionary notes regarding forward-looking statements, indicating that actual results may differ from anticipated outcomes. This secondary offering, while not directly affecting QuidelOrtho's operational strategies, represents a pivotal moment for the company as it navigates through changes in its shareholder base and prepares for future growth in the diagnostics industry.

In related developments, QuidelOrtho continues to focus on enhancing its in vitro diagnostics portfolio, aligning with industry trends that emphasize rapid testing and innovative solutions. The company aims to leverage its strong position in the market to drive advancements in health technology, reinforcing its commitment to improving patient outcomes globally. As the diagnostics landscape evolves, QuidelOrtho's strategies and offerings will be critical in addressing emerging healthcare challenges.